NORTHBROOK, Ill., June 21, 2011 (GLOBE NEWSWIRE) -- Nanosphere, Inc. (Nasdaq:NSPH) announced today it will provide additional information for its premarket approval (PMA) application following the Food and Drug Administration’s (FDA) issuance of a not approvable letter for the Verigene Clopidogrel Metabolism Nucleic Acid Test (Plavix Metabolism).
